CCXI News and Press, ChemoCentryx Inc. From 05/27/22

The following slide deck was published by ChemoCentryx, Inc. in conjunction with this event. For further details see: ChemoCentryx (CCXI) Presents At H.C. Wainwright Global Investment Conference - Slideshow

-- Supports plans to advance TAVNEOS ® (avacopan) into Phase III development for the treatment of patients with most severe form of hidradenitis suppurativa, Hurley Stage III -- SAN CARLOS, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI),...

SAN CARLOS, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 12:30 p.m. ET. The confe...

SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of TAVNEOS ® (avacopan...

Shares of ChemoCentryx (NASDAQ:CCXI) are trading 15% higher on Friday despite Q1 2022 results released after the closing bell Thursday that missed on the top and bottom lines. Today's upside could be because net sales of ~$5.4M in the quarter were five times higher compared to Q4 20...

Gainers: ChemoCentryx (CCXI) +19%. iRhythm Technologies (IRTC) +16%. Jounce Therapeutics (JNCE) +15%. Grifols (GRFS) +9%. Sensus Healthcare (SRTS) +8%. Losers: Joint (JYNT) -46%. Endo International (ENDP) -34%. Guardant Health (GH) -26%. Gain ...

Vinco Ventures (BBIG) +33% on confirming distribution date for planned spin-off of blockchain business Cryptyde. Funko (FNKO) +20% after attracting new investor, striking deal with eBay. Opendoor Technologies (OPEN) +14% on Q1 results. ChemoCentryx (CCXI) +1...

The following slide deck was published by ChemoCentryx, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: ChemoCentryx, Inc. 2022 Q1 - Results - Earnings Call Presentation

ChemoCentryx, Inc. (CCXI) Q1 2022 Earnings Conference Call May 5, 2022, 5:00 PM ET Company Participants Dr. Thomas Schall – Chairman, President and Chief Executive Officer Tausif Butt – Executive Vice President, Chief Operating Officer Susan Kanaya – Executive Vice Presid...

-- Five-fold increase in net sales of TAVNEOS ® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 -- -- Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison): - 195% TAVNEOS new Patient Start Forms - 275% Unique P...